Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk

Anti-CD19 chimeric antigen receptor T (CAR-T) therapy has achieved remarkable effects in refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). However, when high tumor bulk occurs, patients tend to early progression after CAR-T therapy. Here, we investigated whether pretreatment with inte...

Full description

Bibliographic Details
Main Authors: Cuicui Lyu, Rui Cui, Jia Wang, Nan Mou, Yanyu Jiang, Wei Li, Qi Deng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
chimeric antigen receptor
diffuse large B-cell lymphoma
refractory
relapse
debulking chemotherapy
high tumor bulk
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.706087/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.706087/full

Similar Items